12:00 AM
 | 
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Temsirolimus: Phase III data

Top-line data from the open-label, international Phase III INTORACT (B1771006) trial in 800 patients showed that first-line treatment with once-weekly 25 mg IV Torisel plus Avastin bevacizumab every 8 weeks missed the primary endpoint of PFS vs. Avastin plus interferon alfa-2a. Pfizer declined to provide detailed data or next steps, but did say that the study outcome does...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >